{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:16:30Z","timestamp":1774289790448,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jfma.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:39:43Z","timestamp":1697114383000},"page":"551-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Direct oral anticoagulants compared with other strategies in patients with atrial fibrillation and stroke or transient ischemic attack: Systematic review"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7615-9397","authenticated-orcid":false,"given":"Kuan-Hsin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-0141","authenticated-orcid":false,"given":"Wei-Tse","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-9234","authenticated-orcid":false,"given":"Wen-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Ovbiagele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7491-0571","authenticated-orcid":false,"given":"Meng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2023.10.007_bib1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2023.10.007_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2023.10.007_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2023.10.007_bib7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2023.10.007_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib10","doi-asserted-by":"crossref","first-page":"I13","DOI":"10.1093\/eurheartj\/suaa104","article-title":"Non-vitamin k oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation","volume":"22","author":"Diener","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jfma.2023.10.007_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010","article-title":"Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF","volume":"22","author":"Tanahashi","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jfma.2023.10.007_bib12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1212\/WNL.53.6.1319","article-title":"Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke prevention in reversible ischemia trial (SPIRIT). European atrial fibrillation trial (EAFT) study groups","volume":"53","author":"Gorter","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2023.10.007_bib13","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2023.10.007_bib14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2023.10.007_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(22)00302-7","article-title":"Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study","volume":"21","author":"Hobeanu","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2023.10.007_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2023.10.007_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: Development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.jfma.2023.10.007_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jfma.2023.10.007_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2023.10.007_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2023.10.007_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2023.10.007_bib24","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jfma.2023.10.007_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","article-title":"Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial","volume":"11","author":"Diener","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jfma.2023.10.007_bib26","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2023.10.007_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jfma.2023.10.007_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jfma.2023.10.007_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinte.160.1.41","article-title":"Why do patients with atrial fibrillation not receive warfarin?","volume":"160","author":"Bungard","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib30","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.10.007_bib31","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaneurol.2018.2215","article-title":"Association of intracranial hemorrhage risk with non-vitamin k\u00a0antagonist oral anticoagulant use vs aspirin use: a systematic review and meta-analysis","volume":"75","author":"Huang","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jfma.2023.10.007_bib32","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623004072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623004072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:38:14Z","timestamp":1714570694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664623004072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0929664623004072"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2023.10.007","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants compared with other strategies in patients with atrial fibrillation and stroke or transient ischemic attack: Systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}